for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.O

Latest Trade

248.16USD

Change

-9.14(-3.55%)

Volume

3,007,117

Today's Range

246.25

 - 

257.30

52 Week Range

76.59

 - 

331.68

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
257.30
Open
257.30
Volume
3,007,117
3M AVG Volume
100.15
Today's High
257.30
Today's Low
246.25
52 Week High
331.68
52 Week Low
76.59
Shares Out (MIL)
74.48
Market Cap (MIL)
18,483.99
Forward P/E
-24.30
Dividend (Yield %)
--

Next Event

Novavax Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

More

Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published In Lancet Infectious Diseases

Novavax And Serum Institute Of India Announce Submission To World Health Organization For Emergency Use Listing Of Novavax' Covid-19 Vaccine

Novavax Initiates Phase 1/2 Trial Of Combination Vaccine For COVID-19 And Seasonal Influenza

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novavax, Inc.

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry

Biotechnology & Drugs

Contact Info

21 Firstfield Rd

GAITHERSBURG, MD

20878-1757

United States

+1.240.2682000

http://www.novavax.com/

Executive Leadership

James Francis Young

Independent Chairman of the Board

Stanley C. Erck

President, Chief Executive Officer, Director

James Patrick Kelly

Chief Financial Officer, Executive Vice President, Treasurer

Gregory M. Glenn

President, Research and Development

Rick Crowley

Chief Operating Officer, Executive Vice President

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.5K

2021(E)

2.0K
EPS (USD)

2018

-10.000

2019

-5.510

2020

-7.270

2021(E)

-10.214
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.64
Price To Book (MRQ)
24.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
57.72
LT Debt To Equity (MRQ)
44.52
Return on Investment (TTM)
-104.56
Return on Equity (TTM)
-51.60

Latest News

Latest News

Factbox-Latest on the worldwide spread of the coronavirus

Booster shots to bolster immunity against the coronavirus would be free and accessible, U.S. President Joe Biden said on Friday, a day after federal health agencies backed a booster rollout, and he pledged to get his own shot as soon as possible.

Novavax applies to WHO for emergency listing of COVID-19 vaccine

Novavax Inc and its partner Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax's COVID-19 vaccine, potentially clearing the way for the shot to ship to many poorer countries, the company said on Thursday.

Novavax applies to WHO for emergency listing of COVID-19 vaccine

Novavax Inc and its partner Serum Institute of India said on Thursday they had applied to the World Health Organization for an emergency use listing of Novavax's COVID-19 vaccine. (Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)

Novavax expects to make available at least 2 billion COVID-19 vaccine doses in 2022

Vaccine developer Novavax Inc said on Friday at least 2 billion doses of its COVID-19 vaccine would be available in 2022.

Novavax begins early-stage trial for combined influenza/COVID-19 vaccine

Vaccine developer Novavax Inc said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 vaccine.

Novavax COVID-19 vaccine U.S. trial participants count as fully vaccinated two weeks after dosing - CDC

Participants in Novavax Inc's late-stage COVID-19 vaccine trial can be considered fully vaccinated two weeks after completing their two-dose vaccine regimen, the U.S. Centers for Disease Control and Prevention said on Monday.

EU expects key data on Novavax vaccine around October - source

The European Union expects Novavax to submit data needed for the possible approval of its COVID-19 vaccine around October, an EU official told Reuters on Friday, in what could be another delay for the U.S. biotech firm.

Denmark to buy Novavax vaccines as part of EU deal

Denmark said on Wednesday it would buy 280,000 doses of Novavax's potential COVID-19 vaccine for a total price of 37 million Danish crowns ($5.84 million) or roughly $20.9 per dose as part of a European Union agreement with the U.S. company.

Novavax again delays seeking U.S. approval for COVID-19 vaccine

Novavax Inc on Thursday again delayed its timeline for seeking U.S. authorization for its two-dose COVID-19 vaccine but expects to become a major distributor to lower and middle-income countries this year.

BRIEF-Novavax Executive Says Co Has 'Tens Of Millions' Of Shots Already Made; Not Concerned They Will Expire Before They Can Be Used: Conf Call

* NOVAVAX EXECUTIVE SAYS MIGHT PRIORITIZE LOW INCOME COUNTRIES FOR INITIAL VACCINE SUPPLY WHERE THEY WILL BE ABLE TO SUPPORT CRITICAL UNMET DEMAND FOR PRIMARY VACCINATIONS: CONF CALL

Novavax again delays seeking U.S. approval for COVID-19 vaccine

Novavax Inc on Thursday again delayed its timeline for seeking authorization for its two-dose vaccine in the United states, and the company now expects to file for emergency use authorization in the fourth quarter of 2021.

EU seals deal with Novavax for up to 200 million COVID-19 vaccines

The European Commission has approved a supply contract with U.S. firm Novavax to buy up to 200 million doses of its potential COVID-19 vaccine, the Commission said on Wednesday.

WHO warns individuals against mixing and matching COVID vaccines

The World Health Organization's chief scientist has advised individuals against mixing and matching COVID-19 vaccines from different manufacturers, saying such decisions should be left to public health authorities.

Novavax says Taiwan has opted to get firm's COVID-19 vaccine via COVAX

Taiwan has chosen to get the Novavax Inc COVID-19 vaccine via the COVAX global sharing scheme, the company said on Friday, which would add much needed shots to the island's immunisation programme.

Novavax says Taiwan has opted to get firm's COVID vaccine via COVAX

Taiwan has chosen to get the Novavax Inc COVID-19 vaccine via the COVAX global sharing scheme for lower income countries, the company said on Friday, which would add much needed additional shots to the island's immunisation programme.

Factbox: Countries vaccinating children against COVID-19

Moderna is seeking a green light for using its COVID-19 vaccine for teens as young as 12 in the EU, United States and Canada, as Pfizer - whose shot is already being administered - plans tests on even younger children.

Taiwan's COVID-19 cases fall to month-and-a-half low

Taiwan reported on Monday its lowest daily rise in domestic COVID-19 infections in 1-1/2 months, as the island's outbreak stabilises, although the government remains wary about a cluster of the highly contagious Delta variant.

Novavax's COVID-19 vaccine to be made in India soon - govt official

The Serum Institute of India is preparing to produce Novavax's COVID-19 vaccine in the country, government official Vinod Kumar Paul said at a press briefing on Tuesday.

Delta variant doubles risk of hospitalization; Novavax vaccine highly effective in large trial

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Novavax COVID-19 vaccine more than 90% effective in U.S. trial

Novavax Inc on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up